Description:Glecaprevir is an antiviral medication primarily used in the treatment of hepatitis C virus (HCV) infections. It is classified as a direct-acting antiviral (DAA) and functions as a protease inhibitor, specifically targeting the NS3/4A protease enzyme, which is crucial for viral replication. Glecaprevir is often combined with another antiviral agent, pibrentasvir, to enhance its efficacy and broaden the antiviral spectrum. The substance is characterized by its relatively high potency against various HCV genotypes and is administered orally. In terms of its chemical structure, glecaprevir features a complex arrangement of functional groups that contribute to its biological activity and pharmacokinetic properties. It is generally well-tolerated, with a side effect profile that may include fatigue, headache, and gastrointestinal disturbances. Glecaprevir's development represents a significant advancement in hepatitis C treatment, allowing for shorter treatment durations and improved cure rates compared to previous therapies.
We use cookies to enhance your visit. We do not include advertising.
Please see our Cookies Policy for more details or adjust your preferences in "Settings".
This is the advanced settings system for our own and third-party cookies. Here you can modify parameters that will directly affect your browsing experience on this website. If you wish you may check the list of Cookie types.
Please note that disabling cookies can cause failures in the normal operation of the web.
